JZJT Pharmaceutical’s Revenue from Healthcare Products Decreased by 20%
date:2017-01-19
browse:(797)
Keyword:
In 2016, JZJT (600750)’s operating revenue decreased by 39.87%, realizing ¥1,562 million; whereas its net profit reached ¥380 million with a year-on-year growth of 3.47%. Regardless of the impact brought by the external transfer of Jiangxi Jointown Pharmaceutical in 2015, the operating revenue decreased by 12.09% on year-on-year basis.
Among which, the area of “healthcare food and others” relying mainly on Chuenu series and Shenlingcao Oral Liquid etc. realized annual operating revenue of ¥240 million which decreased by 23.33% year-on-year.
Among which, the area of “healthcare food and others” relying mainly on Chuenu series and Shenlingcao Oral Liquid etc. realized annual operating revenue of ¥240 million which decreased by 23.33% year-on-year.
The latest article
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year